Categories Retail, U.S. Markets News
Goldman downgrade is a call for Walgreens to revisit biz strategy
Shares of pharmacy store chain Walgreens Boots Alliance Inc. (WBA) dropped sharply Friday after they were downgraded by Goldman Sachs, in what could be an alert against the growing presence of online players like Amazon (AMZN) in the pharma retail space. The price target on the stock was lowered to $68, significantly below Friday’s opening price.
Citing the challenges facing the retail pharmacy business, the research firm cut its rating on Walgreens to sell from neutral. The stock has been on a downward spiral after hitting a three-year high earlier this month. It gained about 10% since the beginning of the year.
Citing the challenges facing the retail pharmacy business, the research firm cut its rating on Walgreens to sell from neutral
Analysts are of the view that the management’s present strategy, marked by business partnerships across multiple sectors, is inadequate to sustain growth. Most of the company’s tie-ups are structured to increase footfall in its stores, which according to the analysts is an ineffective method to counter the growing threat from online drug retailers.
The new rating – the only sell tag on the company currently – could be a dampener as far as investors are concerned. The majority of other market watchers recommends either buy or hold for Walgreens.
The downgrade comes in the midst of hectic merger activity in the sector, which recently witnessed Walgreens’ arch-rival CVS Health (CVS) acquiring Aetna (AET), a leading health insurance firm, and Amazon boosting its online drug delivery service by adding PillPack into its fold.
Soon after each of the high-value deals involving online retailers, investor sentiment turned bearish causing the stocks of pharma store operators to fall sharply. For Walgreens, the chances of retaining the growth momentum through acquisitions are bleak due to its high debt and unimpressive cash flow.
Adding to the woes of conventional store operators, President Donald Trump recently raised concerns about the high costs of pharmaceutical products including medicine, forcing several companies to slash their prices.
Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text
Most Popular
Tyson Foods (TSN) Q1 2023 Earnings: Key financials and quarterly highlights
Tyson Foods Inc. (NYSE: TSN) reported first quarter 2023 earnings results today. Sales rose 2.5% year-over-year to $13.2 billion. Net income attributable to Tyson was $316 million, or $0.88 per
After weak start to 2023, Apple (AAPL) sees some bright spots
Apple Inc. (NASDAQ: AAPL) this week reported its first revenue decline in more than three years, even as the high inflation continues to squeeze customers’ spending power. Sales of the
Earnings: Qualcomm (QCOM) Q1 profit falls on lower revenues
Chipmaker Qualcomm, Inc. (NASDAQ: QCOM) has reported lower earnings and revenues for the first quarter of 2023. The company also provided guidance for the second quarter of 2023. At $9.5